Shares of Marksans Pharma Ltd soared 3% on 6 November after the company announced securing approval from the UK MHRA for its cancer medicine. 

The company’s wholly owned subsidiary, Relonchem, in the United Kingdom, has gained marketing authorisation from the UK Medicines and Healthcare Products Regulatory Agency for its product Exemestane 25 mg film-coated tablets.

The board of directors of the firm will meet on 13 November 2025 to evaluate and approve the business’s unaudited financial results (both standalone and consolidated) for the quarter and half-year ended 30 September 2025.

Earlier, in October, the UK MHRA granted Relonchem marketing clearance for Clonidine 100 microgram tablets and Clonidine Hydrochloride 25 microgram tablets.

On 5 December 2024 and 7 October 2025, the share reached a 52-week high of Rs 358.50 and a low of Rs 162.05, respectively.

However, at 12:50 pm, the shares of Marksans Pharma shed all their gains and were trading % lower at Rs 185.60 on NSE.

Ready to invest like a pro? Unicorn Signals app equips you with 100+ Free tools and knowledge you need to succeed. Download the Unicorn Signals app and gain access to daily stock lists and insightful market analysis and much more!